PMID- 25806279
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150325
LR  - 20210102
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 3
IP  - 1
DP  - 2014 Feb
TI  - Immunotherapy prospects in the treatment of lung cancer and mesothelioma.
PG  - 34-45
LID - 10.3978/j.issn.2218-6751.2013.11.04 [doi]
AB  - A very recent finding is the role of immune activation in cancer. The assumption 
      that stimulating the patient's immune system to attack tumors is a valuable 
      treatment option in malignant diseases has gained more acceptance. However the 
      high immunosuppressive effects caused by the tumor limits this beneficial effect. 
      There is a delicate balance between immunoactivation and immunosuppression in a 
      patient. Especially in non small cell lung cancer (NSCLC), the role of 
      immunosuppressive cells hampering immune activation is high. But also in small 
      cell lung cancer (SCLC) and mesothelioma immunosuppressive activity is high. This 
      is suggested to be related to the type of tumor, advanced stage of the disease, 
      and the tumor load. In this review, we provide an overview of the progress and 
      challenges in the immunotherapeutic approaches in lung cancer. We conclude with 
      the concept that immunotherapy in thoracic malignancies must be tailored made to 
      the balance of the immune system.
FAU - Aerts, Joachim G
AU  - Aerts JG
AD  - 1 Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands ; 2 Department of Pulmonary Diseases, Amphia Hospital Breda, The 
      Netherlands.
FAU - Lievense, Lysanne A
AU  - Lievense LA
AD  - 1 Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands ; 2 Department of Pulmonary Diseases, Amphia Hospital Breda, The 
      Netherlands.
FAU - Hoogsteden, Henk C
AU  - Hoogsteden HC
AD  - 1 Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands ; 2 Department of Pulmonary Diseases, Amphia Hospital Breda, The 
      Netherlands.
FAU - Hegmans, Joost P
AU  - Hegmans JP
AD  - 1 Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Rotterdam, The 
      Netherlands ; 2 Department of Pulmonary Diseases, Amphia Hospital Breda, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC4367611
OTO - NOTNLM
OT  - Non small cell lung cancer (NSCLC)
OT  - immune checkpoint antibodies
OT  - immunotherapy
EDAT- 2015/03/26 06:00
MHDA- 2015/03/26 06:01
PMCR- 2014/02/01
CRDT- 2015/03/26 06:00
PHST- 2013/09/11 00:00 [received]
PHST- 2013/11/25 00:00 [accepted]
PHST- 2015/03/26 06:00 [entrez]
PHST- 2015/03/26 06:00 [pubmed]
PHST- 2015/03/26 06:01 [medline]
PHST- 2014/02/01 00:00 [pmc-release]
AID - tlcr-03-01-034 [pii]
AID - 10.3978/j.issn.2218-6751.2013.11.04 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2014 Feb;3(1):34-45. doi: 
      10.3978/j.issn.2218-6751.2013.11.04.